Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use

Nephrology

Volumn 20, Issue 12, 2015, Pages 931-935

  Chuang, Gwo Tsann ^a   Tsai, I Jung ^a   Tsau, Yong Kwei ^a   Lu, Meng Yao ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

deferariox; Fanconi syndrome; hypophosphataemia; renal tubular acidosis; Thalassaemia

Indexed keywords

CREATININE; DEFERASIROX; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ARTICLE; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG SAFETY; FANCONI RENOTUBULAR SYNDROME; FEMALE; HUMAN; HYPOPHOSPHATEMIA; INCIDENCE; KIDNEY TUBULE ACIDOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THALASSEMIA; TREATMENT DURATION; TREATMENT WITHDRAWAL; ADOLESCENT; BLOOD; BLOOD TRANSFUSION; CHEMICALLY INDUCED; FANCONI SYNDROME; PRESCHOOL CHILD; RISK FACTOR; TAIWAN; UNIVERSITY HOSPITAL; YOUNG ADULT;

ACIDOSIS, RENAL TUBULAR; ADOLESCENT; BENZOATES; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FANCONI SYNDROME; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; HYPOPHOSPHATEMIA; INCIDENCE; IRON CHELATING AGENTS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; THALASSEMIA; TRIAZOLES; YOUNG ADULT;

EID: 84945551901     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12523     Document Type: Article

References (23)

1. Olivieri NF,. The beta-thalassemias. N. Engl. J. Med. 1999; 341: 99-109.
2. De Sanctis V, Roos M, Gasser T, et al. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J. Pediatr. Endocrinol. Metab. 2006; 19: 471-480.
3. Hershko C, Link G, Konijn AM, Cabantchik ZI,. Objectives and mechanism of iron chelation therapy. Ann. N. Y. Acad. Sci. 2005; 1054: 124-135.
4. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br. J. Haematol. 2007; 136: 501-508.
5. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-3462.
6. Raphael JL, Bernhardt MB, Mahoney DH, et al. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr. Blood Cancer 2009; 52: 616-620.
7. Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M,. Fanconi syndrome due to deferasirox. Am. J. Kidney Dis. 2009; 54: 931-934.
8. Papadopoulos N, Vasiliki A, Aloizos G, Tapinis P, Kikilas A,. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann. Pharmacother. 2010; 44: 219-221.
9. Even-Or E, Becker-Cohen R, Miskin H,. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am. J. Hematol. 2010; 85: 132-134.
10. Yacobovich J, Stark P, Barzilai-Birenbaum S, et al. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. J. Pediatr. Hematol. Oncol 2010; 32: 564-567.
11. Grangé S, Bertrand DM, Guerrot D, Eas F, Godin M,. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol. Dial. Transplant. 2010; 25: 2376-2378.
12. Rheault MN, Bechtel H, Neglia JP, Kashtan CE,. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr. Blood Cancer 2011; 56: 674-676.
13. Wei HY, Yang CP, Cheng CH, Lo FS,. Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months. Transfusion 2011; 51: 949-954.
14. Dell'Orto VG, Bianchetti MG, Brazzola P,. Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: A case report and review of the literature. J. Clin. Pharm. Ther. 2013; 38: 526-527.
15. Murphy N, Elramah M, Vats H, Zhong W, Chan MR,. A case report of deferasirox-induced kidney injury and Fanconi syndrome. WMJ 2013; 112: 177-180.
16. Dee CM, Cheuk DK, Ha SY, Chiang AK, Chan GC,. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia. Br. J. Haematol. 2014; 167: 434-436.
17. Baum M,. Renal Fanconi syndrome secondary to deferasirox: Where there is smoke there is fire. J. Pediatr. Hematol. Oncol 2010; 32: 525-526.
18. Perkins NJ, Schisterman EF,. The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am. J. Epidemiol. 2006; 163: 670-675.
19. Diaz-Garcia JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Nino MD, Villarrubia J, Ortiz A,. Deferasirox nephrotoxicity-the knowns and unknowns. Nat. Rev. Nephrol. 2014; 10: 574-586.
20. Hsu SY, Tsai IJ, Tsau YK,. Comparison of growth in primary Fanconi syndrome and proximal renal tubular acidosis. Pediatr. Nephrol. 2005; 20: 460-464.
21. De Sanctis V, Soliman A, Yassin M,. Iron overload and glucose metabolism in subjects with beta-thalassaemia major: An overview. Curr. Diabetes Rev. 2013; 9: 332-341.
22. Siddappa S, Mythri KM, Kowsalya R, Parekh A,. Refractory anemia leading to renal hemosiderosis and renal failure. Indian J. Pathol. Microbiol. 2011; 54: 379-380.
23. Ozkurt S, Acikalin MF, Temiz G, Akay OM, Soydan M,. Renal hemosiderosis and rapidly progressive glomerulonephritis associated with primary hemochromatosis. Ren. Fail. 2014; 36: 814-816.